岁末微寒，又是一年过去了，你的身体还好吗？把"爱我老己"挂嘴边的你，真的有好好爱自己吗？ 12月26日，"智汇资本，悦想健康"为主题的广东资本圈健康沙龙，在深圳成功举办。本次活动由证券时 报华南总部、新财富杂志社联合主办，东阳光（600673）鲜虫草协办，包括多家上市公司高管、金融机 构大咖等30余位资本圈嘉宾参与此次活动。 在快节奏、高压力的资本圈，健康是个人最宝贵的资产，也是持续创造价值的基石。本次健康沙龙旨在 关注资本市场从业者的身心健康，搭建一个放松身心、交流健康管理经验的专属平台。 本次沙龙活动融合了传统养生智慧与现代健康理念，倡导"健康生活、投资健康"的新风尚，精准助力每 一位行业精英以最佳状态应对挑战，赋能长远发展。（文穗） 未来，证券时报华南总部不仅要做华南资本圈权威的信息传播平台与高效的资源对接纽带，更要争做健 康生态的共创者，持续整合多方优质资源，通过健康沙龙、实地参访等形式，将科学的健康管理方案精 准送达每一位奋斗者身边，助力大家在高质量发展之路上，既能乘风破浪，亦能从容安康。 东阳光虫草深圳总经理刘斌表示，优秀的企业不仅是财富的创造者，更应该是健康理念的推动者。东阳 光长期致力于健康公 ...

Group 1 - The eighth China International Import Expo concluded on November 10, showcasing a significant trend where companies with consumer-facing (TOC) businesses actively engaged in live streaming sales, with notable performances from various influencers [1] - TIMESHOP's collaboration with influencer Yuan Zhe resulted in a GMV exceeding 3 million during the expo for their "Double A Products," highlighting the effectiveness of live commerce in driving sales [1][3] - The "Double A Products," which include "Yihuo New AKG PRO" and "Chao Bei Qing AKK BOOM," have gained substantial market attention, with "Yihuo New AKG PRO" achieving monthly sales of 100,000 bottles since its launch in March [3] Group 2 - TIMESHOP's flagship product "Yishenghao 21000" has consistently topped sales charts on platforms like JD and Tmall, boasting a user repurchase rate exceeding 80% and winning multiple awards, including the 2023 CAPITAL Anti-Aging Innovation Technology Brand Award [5] - The company emphasizes the importance of health in longevity, aiming to shift preventive medicine from hospitals to everyday life through accessible and verifiable products [5] - TIMESHOP plans to enhance its research and investment efforts both domestically and internationally, collaborating with global experts to improve product scientific content and promote sustainable health lifestyles to Chinese consumers [7]

Core Perspective - The release of the "Healthy China 2030 Planning Outline" signifies a profound shift in China's health care system from a "disease-centered" model to a "people-centered" approach, emphasizing prevention and the need for a robust preventive medical system [1] Group 1: Resource Allocation and Optimization - The concentration of quality medical resources in large public hospitals has led to high operational loads, with 9.55 billion total medical visits reported in 2023, many of which are for routine checks rather than urgent care [2][3] - The growth of professional health examination institutions provides an efficient "diversion" channel, allowing public hospitals to focus on critical medical challenges while meeting preventive health needs in a more optimized environment [3] Group 2: Enhancing Public Health Awareness - The entry of social capital into the health examination market has significantly increased service accessibility and frequency, transforming annual health checks from a privilege to a standard practice for the majority [4] - Market competition has driven profound changes in service models, with institutions focusing on improving service experiences and educating the public on health management tailored to different age groups [4] Group 3: Innovation in Service Models - The innovations in service models and management mechanisms by private institutions contribute qualitatively to the healthcare system, creating a "catalytic" effect that enhances overall service quality [5][6] - These institutions are adopting digital health accounts and integrating AI technologies into various health services, improving diagnostic efficiency and pushing for technological advancements in the industry [6] Group 4: Collaborative Ecosystem - The collaboration between public and private healthcare entities is essential for deepening the preventive medical system, ultimately aiming for comprehensive health and well-being for all citizens [7]

Group 1 - HPV infection is a significant global public health issue, and the HPV vaccine is a crucial component of public health systems, especially with the promotion of strategies like the "Global Strategy to Accelerate the Elimination of Cervical Cancer" and "Healthy China Strategy" [1] - The introduction of domestic nine-valent HPV vaccines has sparked discussions on how to choose the best vaccine, highlighting the decision-making challenges faced by consumers [1] - Merck holds a leading position in the HPV vaccine market with its Gardasil®9, the only nine-valent vaccine approved for preventing cervical cancer caused by seven high-risk HPV types, and it is also the first and only nine-valent HPV vaccine approved for both males and females in China [1] Group 2 - Merck has a long history in vaccine development, having established itself as a key player in the global vaccine field since its founding in 1891, with significant contributions such as the transfer of hepatitis B vaccine technology to China [2] - The development of the HPV vaccine by Merck is rooted in a commitment to preventive medicine, emphasizing the importance of long-term efforts to ensure the vaccine's effectiveness over time [2] - The research and development of the HPV vaccine also benefited from Chinese scientific advancements, particularly the breakthroughs achieved by Chinese scientist Dr. Zhou Jian in the 1990s [2] Group 3 - As of May 2025, Merck's nine-valent HPV vaccine has been administered over 400 million doses globally, covering 112 countries, and has protected over 33 million eligible women in China since its approval in 2018 [3] - Long-term monitoring in countries like Australia has shown significant reductions in the incidence of HPV-related diseases following the implementation of vaccination programs, reinforcing the vaccine's effectiveness [3] - The stability of safety and efficacy data across different regions and time periods is a critical factor for healthcare providers and parents when choosing vaccines [3] Group 4 - Merck's Gardasil®9 utilizes a more mature yeast expression system, which enhances immunogenicity and reduces contamination risks, providing dual assurance of safety and efficacy [4] - The HPV vaccine market is transitioning from a "single supply" to "multiple competition," with Merck leveraging its extensive clinical data and global experience to offer reliable options for diverse consumer needs [4]

Investment Rating - The report does not explicitly provide an investment rating for the wearable health monitoring devices industry Core Insights - The wearable health monitoring devices industry in China is transitioning from basic step counting to medical-grade monitoring, driven by hardware innovation and data intelligence [2] - The demand for precise health monitoring is increasing, particularly due to the aging population and rising chronic disease rates, which is propelling the growth of wearable health monitoring devices [2][23] - The industry is characterized by a dual-track competition between medical companies and technology giants, with companies like Ji'an and Leshi leading the medical-grade sector, while Huawei, Apple, and Xiaomi dominate the consumer-grade market [3][4] Summary by Sections Overview - Wearable health monitoring devices are multifunctional technology devices that collect physiological data to support health management, categorized into consumer-grade and medical-grade products [2][10] - The industry has established a policy support system that integrates technological innovation, standardization, and application scenarios, providing a comprehensive framework for development [2] Market Demand - The aging population in China is expected to reach 380 million by 2030, creating a strong need for real-time health monitoring solutions that wearable devices can provide [23][26] - The prevalence of chronic diseases is rising, further increasing the demand for continuous health monitoring [26] Market Size - The market for wearable health monitoring devices in China is projected to grow from 1,400.2 billion yuan in 2020 to 2,230.2 billion yuan by 2029, with a compound annual growth rate (CAGR) of 7.0% from 2025 to 2029 [31][33] - The market experienced a decline in 2022 due to high base effects and global economic pressures, but is expected to recover with policy support and technological advancements [33] Industry Chain Analysis - The industry chain consists of upstream hardware and software suppliers, midstream manufacturers, and downstream sales channels that reach end-users [37][40] - The sensor market is expected to grow at a CAGR of 15.0% over the next three years, highlighting the importance of sensor technology in wearable devices [42][44] Competitive Landscape - The competition in the wearable health monitoring devices market is intensifying, with a convergence of consumer-grade and medical-grade products [74][76] - Medical companies are leveraging their expertise to enter the consumer market, while technology companies are enhancing their health monitoring capabilities to penetrate the medical sector [76]